>
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Conventional antibody discovery is a lengthy process that involves a myriad of different technologies that need to be assembled before a commercial antibody can be produced. The integration of: (i) library design, (ii) display methodology, (iii) reformatting between different hosts and expression constructs, and (iv) GMP cell line development is resource intensive, time consuming, and typically results in extensive royalty obligations to multiple third parties.
Adimab was founded by two of the world's leading yeast biotechnologists: Professor Tillman Gerngross (Dartmouth, Co-founder of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) who led the humanization effort to engineer yeast for the production of human glycoproteins, and Professor Dane Wittrup (MIT, Co-founder of Biodisplay, acquired by Abbott Labs in 2001.) who pioneered yeast surface display for the discovery and maturation of antibody fragments.